Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats (Q46769723)

25 December 2017

title

Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats (English)

1 reference

25 December 2017

0 references

0 references

0 references

I Kunz

1

1 reference

25 December 2017

M K Meier

2

1 reference

25 December 2017

A Bourson

3

1 reference

25 December 2017

M Fisseha

4

1 reference

25 December 2017

W Schilling

5

1 reference

25 December 2017

language of work or name

English

0 references

publication date

5 February 2008

1 reference

25 December 2017

International Journal of Obesity

published in

1 reference

25 December 2017

volume

32

1 reference

25 December 2017

page(s)

863-870

1 reference

25 December 2017

issue

5

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/ijo.2008.3

exact match

0 references

cites work

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Practical aspects of indirect calorimetry in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Adiponectin, the missing link in insulin resistance and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Visfatin: the missing link between intra-abdominal obesity and diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

The endocannabinoid system: body weight and metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Activation of the peripheral endocannabinoid system in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Endocannabinoids and the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

Plasma adiponectin levels are not associated with fat oxidation in humans

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2008.3

7 January 2021

Identifiers

DOI

10.1038/IJO.2008.3

1 reference

25 December 2017

PubMed ID

18253160

1 reference

25 December 2017